These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 14664733)

  • 41. Papillary serous cystadenocarcinoma of the stomach, peritoneum and ovary.
    Yen CC; Tsai CS; Hsi SC; Yang YS
    Acta Gastroenterol Belg; 2009; 72(4):462. PubMed ID: 20163045
    [No Abstract]   [Full Text] [Related]  

  • 42. [Paraneoplastic cerebellar degeneration (PCD) with anti-Yo antibodies in ovarian carcinoma].
    Holzmann P; Holy D; Stillhard G; Janda M; Möbr P
    Schweiz Med Wochenschr; 1998 Jun; 128(23):906-8. PubMed ID: 9658519
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
    Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical management of uterine papillary serous carcinoma.
    Roelofsen T; van Ham MA; de Hullu JA; Massuger LF
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):71-81. PubMed ID: 21166512
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Precursor lesions of type II endometrial cancer: diagnostic criteria and pathogenesis].
    Wang HJ; Zheng WX
    Zhonghua Bing Li Xue Za Zhi; 2007 Aug; 36(8):505-7. PubMed ID: 17980094
    [No Abstract]   [Full Text] [Related]  

  • 46. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary.
    Bloss JD; Liao SY; Buller RE; Manetta A; Berman ML; McMeekin S; Bloss LP; DiSaia PJ
    Gynecol Oncol; 1993 Sep; 50(3):347-51. PubMed ID: 8406199
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Four primary malignancies successively occurred in a BRCA2 mutation carrier: a case report.
    Fruscalzo A; Damante G; Calcagno A; Di Loreto C; Marchesoni D
    Cancer Invest; 2006 Oct; 24(6):611-4. PubMed ID: 16982466
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Ovarian cancer and dermatomyositis. A clinical case].
    Gómez R; Oyarzún E; Cortínez A; Barrena N; Massardo L; Wild R
    Rev Med Chil; 1992 Oct; 120(10):1149-52. PubMed ID: 1341778
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of ovarian cancer in young women.
    Gershenson DM
    Clin Obstet Gynecol; 2012 Mar; 55(1):65-74. PubMed ID: 22343230
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recurrent ovarian carcinoma presenting as a solitary metastasis to the kidney.
    Thyagarajan MS; Abdi S
    Br J Radiol; 2008 Dec; 81(972):e293-4. PubMed ID: 19029051
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.
    Vogel TJ; Knickerbocker A; Shah CA; Schiff MA; Isacson C; Garcia RL; Goff BA
    J Gynecol Oncol; 2015 Jan; 26(1):25-31. PubMed ID: 25376917
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study.
    Young RC; Brady MF; Nieberg RK; Long HJ; Mayer AR; Lentz SS; Hurteau J; Alberts DS
    J Clin Oncol; 2003 Dec; 21(23):4350-5. PubMed ID: 14645424
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low grade serous ovarian carcinoma with metastases to the sternum and ribs.
    McGrath S; Madhuri TK; Susarla S; Haagsma B; Saleh F; Michael A
    Pathology; 2012 Aug; 44(5):481-2. PubMed ID: 22744167
    [No Abstract]   [Full Text] [Related]  

  • 54. Ovarian serous surface papillary borderline tumors form sea anemone-like masses.
    Tanaka YO; Okada S; Satoh T; Matsumoto K; Oki A; Nishida M; Yoshikawa H; Saida T; Minami M
    J Magn Reson Imaging; 2011 Mar; 33(3):633-40. PubMed ID: 21287653
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.
    Kelly MG; O'Malley D; Hui P; McAlpine J; Dziura J; Rutherford TJ; Azodi M; Chambers SK; Schwartz PE
    Gynecol Oncol; 2004 Dec; 95(3):469-73. PubMed ID: 15581948
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular subtypes of high-grade serous ovarian cancer: the holy grail?
    Waldron L; Riester M; Birrer M
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25269490
    [No Abstract]   [Full Text] [Related]  

  • 57. [Clinical significance of two-tier grading system of ovarian serous carcinoma].
    Zhang J; Guo XQ; Liu JS
    Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):739-41. PubMed ID: 22321346
    [No Abstract]   [Full Text] [Related]  

  • 58. Cystic neoplasms of the exocrine pancreas.
    Campbell F; Azadeh B
    Histopathology; 2008 Apr; 52(5):539-51. PubMed ID: 17903202
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
    da Costa AA; Valadares CV; Baiocchi G; Mantoan H; Saito A; Sanches S; Guimarães AP; Achatz MI
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S971-8. PubMed ID: 26014155
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Solitary brain metastasis in a patient with ovarian cancer with BRCA2 mutation.
    Root K; Armaghany T
    J Clin Oncol; 2012 Sep; 30(25):e239-40. PubMed ID: 22753899
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.